| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 33.19 | 4.4% | 16.0% |
| Total Income | 33.45 | 8.7% | 12.2% |
| Expenditure | 41.68 | 6.6% | 18.2% |
| PBT | -8.23 | 3.1% | 392.9% |
| Net Profit | -8.08 | 9.2% | 498.4% |
| OPM | -11.54% | 8.90pp | 3.08pp |
| NPM | -24.14% | 3.96pp | 29.46pp |
| EPS | 6.24 | 7.0% | 225.0% |
Pharma manufacturer swung to a net loss (NPM -24.1% vs +5.3% YoY) as expenses grew 18% against flat core revenue and last year's other-income cushion evaporated, despite topline revenue growth of 16%.
Kerala Ayurveda Reaffirms ₹1000 Cr Revenue Goal by FY30
12 Aug 2026 · 12 Aug, 7:23 pm
Summary
Kerala Ayurveda Ltd (KAL) announced its Q1 FY 27 financial results, reaffirming its path to ₹1,000 Crs. by FY 2030. Revenue from operations grew by 16.0% year-on-year to ₹33.2 Crs., with standalone business revenue up 28.3% to ₹22.5 Crs. The company reported a significant improvement in its Operating EBITDA (Adj.), with the loss halving sequentially to ₹-3.82 Crs. from ₹-7.10 Crs. in the prior quarter. Management is focused on achieving Operating EBITDA breakeven by September 2026 through cost optimization, business scale-up, and restructuring of loss-making units.
Key Highlights
- 1
Revenue from operations increased 16.0% to ₹33.2 Crs. in Q1 FY 27 compared to the same quarter of the previous year.
- 2
Standalone business revenue from operations increased 28.3% to ₹22.5 Crs. in Q1 FY 27 compared to the same quarter of the previous year.
- 3
Operating EBITDA (Adj.) loss halved sequentially to ₹-3.82 Crs. in Q1 FY 27, from ₹-7.10 Crs. in Q4 FY 26.
- 4
Global E-Product revenue saw a growth of 32.3% YoY, exceeding expectations.
- 5
The company reaffirms its Vision 2030 ambition to scale consolidated revenue to ₹1,000 Crs. by FY30.
- 6
New clinics are planned in San Jose, Eindhoven, and India, with two new resorts in the pipeline, by November 2026.
Informational and educational content only. Not investment advice.